USP1 Inhibition Triggers PCNA Degradation via RAD18, Exposing BRCA1 Cancer Vulnerability
For the roughly 5–10% of breast and ovarian cancers driven by BRCA1 loss, finding drugs that selectively kill deficient cells while sparing healthy ones…
Found 1710 results for "cancer"
For the roughly 5–10% of breast and ovarian cancers driven by BRCA1 loss, finding drugs that selectively kill deficient cells while sparing healthy ones…
Pancreatic cancer kills roughly 88% of patients within five years, largely because its dense, immunosuppressive tumor microenvironment renders most therapies…
Achieving viral cure from hepatitis C does not eliminate liver cancer risk — a finding with profound implications for the estimated 57 million people living…
When financial conflicts of interest are this pervasive across every decision-making node in oncology — from the researchers designing trials to the patient…
Few medical screening debates have persisted as long or as contentiously as PSA testing for prostate cancer. A decade ago, the evidence suggested screening…
Breast cancer incidence rises sharply after menopause, yet the biological mechanisms underlying that surge have remained frustratingly incomplete. New…
As millions of adults begin long-term GLP-1 and dual GLP-1/GIP receptor agonist therapy, the clinical conversation is shifting from efficacy to safety of…
Screening numbers have long served as the headline measure of healthy-aging programs, but counting how many older adults are tested reveals almost nothing…
For decades, the dominant clinical concern around testosterone in men has been its potential to fuel prostate cancer growth. This large-scale meta-analysis…
For patients carrying rare DNA-repair gene mutations in cancers that fall outside olaparib's approved indications, treatment options after standard therapies…
One of the most stubborn problems in thoracic oncology is that KRAS-mutant lung cancers — among the most common oncogene-driven malignancies — resist both…
Prostate cancer disparities between Black and White men remain one of oncology's most persistent and poorly explained gaps — and a new narrative review…
For decades, cisplatin-based chemotherapy before radical bladder removal has been the best available option for muscle-invasive bladder cancer — a disease…
Understanding how breast tumors evade immune surveillance remains one of oncology's central challenges, and any molecular axis that sits at that intersection…
For the millions of women carrying BRCA1 mutations who may one day rely on targeted immunotherapies, the accuracy of the molecular tools used to measure gene…
Understanding how immune cells commit to a specific identity — and stay committed — has profound implications for cancer immunotherapy, autoimmunity, and…
A prospective cohort study enrolling 100 women with histologically confirmed breast cancer in Tehran, Iran, will capture nine repeated dietary records across…
The race to make personalized cancer vaccines clinically practical has been stalled not by biology but by manufacturing. A patient whose tumor is sequenced in…
Glioblastoma remains one of the most treatment-resistant cancers known, in large part because the blood–brain barrier blocks most therapeutic agents from ever…
Iron deficiency remains the world's most prevalent nutritional disorder, yet the molecular machinery governing how cells absorb iron with precision has…